Neutrophil recruitment by CD4 tissue-resident memory T cells induces chronic recurrent inflammation in atopic dermatitis

Clinical Immunology, Год журнала: 2023, Номер 256, С. 109805 - 109805

Опубликована: Окт. 11, 2023

Язык: Английский

---

Advances in skin gene therapy: utilizing innovative dressing scaffolds for wound healing, a comprehensive review

Journal of Materials Chemistry B, Год журнала: 2024, Номер 12(25), С. 6033 - 6062

Опубликована: Янв. 1, 2024

Gene-activated matrices are versatile and novel technologies to treat skin wounds. This approach offers a promising avenue for targeted treatment strategies in health care.

Язык: Английский

---

IL-22 in Atopic Dermatitis

Cells, Год журнала: 2024, Номер 13(16), С. 1398 - 1398

Опубликована: Авг. 22, 2024

Atopic dermatitis (AD) is a prevalent and chronic inflammatory skin condition characterized by multifaceted pathophysiology that gives rise to diverse clinical manifestations. The management of AD remains challenging due the suboptimal efficacy existing treatment options. Nonetheless, recent progress in elucidating underlying mechanisms disease has facilitated identification new potential therapeutic targets promising drug candidates. In this review, we summarize newest data, considering multiple connections between IL-22 AD. presence circulating been found correlate with severity identified as critical factor driving response associated condition. Elevated levels patients are correlated increased proliferation keratinocytes, alterations microbiota, impaired epidermal barrier function. Collectively, these factors contribute manifestation characteristic symptoms observed

Язык: Английский

---

LIGHT signaling through LTβR and HVEM in keratinocytes promotes psoriasis and atopic dermatitis-like skin inflammation

Journal of Autoimmunity, Год журнала: 2024, Номер 144, С. 103177 - 103177

Опубликована: Фев. 17, 2024

Язык: Английский

---

Yu-Ping-Feng-San alleviates inflammation in atopic dermatitis mice by TLR4/MyD88/NF-κB pathway

Journal of Ethnopharmacology, Год журнала: 2024, Номер 329, С. 118092 - 118092

Опубликована: Апрель 9, 2024

Язык: Английский

---

Identification of a dual JAK3/TEC family kinase inhibitor for atopic dermatitis therapy

Biochemical Pharmacology, Год журнала: 2025, Номер 232, С. 116740 - 116740

Опубликована: Янв. 5, 2025

Язык: Английский

---

Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children

Dermatology and Therapy, Год журнала: 2025, Номер unknown

Опубликована: Янв. 7, 2025

Tapinarof is a topical aryl hydrocarbon receptor (AhR) agonist in development for the treatment of atopic dermatitis (AD). In two phase 3 trials (ADORING 1 and 2), tapinarof cream 1% once daily (QD) demonstrated significant efficacy was well tolerated patients down to age 2 years with AD. Here, we evaluate patient-reported outcomes (PROs), including family impact, ADORING 2. 2, 813 were randomized or vehicle QD 8 weeks. PROs assessed using Dermatology Life Quality Index (DLQI), Children's (CDLQI), Infants' Dermatitis (IDQOL), Family Impact Questionnaire (DFI), Patient Oriented Eczema Measure (POEM). Mean baseline DLQI, CDLQI, IDQOL, DFI scores indicated that impact on families patients' quality life (QoL) AD moderate very large. POEM severe symptoms at baseline. improved QoL versus across all endpoints week 8: − 6.2 vs 3.5 (P = 0.0031) 5.5 0.0028); DFI, 5.6 2.9 < 0.0001) 3.8 0.0037), respectively. Similar improvements CDLQI IDQOL reported vehicle. also significantly sleep subdomain vehicle: ≥ 12 years, 9.4 5.3 10.6 3.6 (both P 0.0001); 11.4 5.7 0.0001), 10.8 7.3 0.0005). PROs, regardless age, from (the earliest evaluation) through 8. once-daily, non-steroidal rapidly improves symptoms, sleep, Clinical Trials.gov identifier: NCT05014568; NCT05032859.

Язык: Английский

---

Tapinarof cream 1% once daily was well tolerated in adults and children with atopic dermatitis in two phase 3 randomized trials

Journal of Dermatological Treatment, Год журнала: 2025, Номер 36(1)

Опубликована: Янв. 12, 2025

Background: Tapinarof cream 1% once daily (QD) demonstrated significant efficacy in patients down to age 2 years with atopic dermatitis (AD) the ADORING 1 and phase 3 trials. We report local tolerability outcomes.Methods: Patients received or vehicle QD for 8 weeks. Tolerability was evaluated using patient/parent/caregiver investigator 5-point Local Scales (LTS). Investigators assessed sensitive skin areas, including face/neck.Results: 813 were randomized (∼80% pediatric). Mean pretreatment baseline overall LTS scores similar across groups trials: 1.0–1.9 (patient-assessed) indicating slight burning/stinging itching; 0.3–0.6 (investigator-assessed) no-to-minimal irritation. well tolerated improvement from itching first application through Week (patient-reported): mean 0.2–0.4 (burning/stinging) 0.6–0.8 (itching). reported irritation (dryness/erythema/peeling) (mean scores: 0.2 0.1 2, respectively). Across skin, investigators [Tapinarof versus vehicle]: 0–0.3 0–1.0).Conclusion: locally 8, on areas.

Язык: Английский

---

The Origin, Intricate Nature, and Role of the Skin Surface pH (pHSS) in Barrier Integrity, Eczema, and Psoriasis

Cosmetics, Год журнала: 2025, Номер 12(1), С. 24 - 24

Опубликована: Фев. 3, 2025

The inherent acidic nature of the stratum corneum (SC), so-called “acid mantle”, has a multitude effects on skin barrier integrity owing to its (patho)physiological role in homeostasis, antimicrobial defense, and inflammation. Several salient SC acidifying mechanisms, including breakdown FLG (filaggrin) protein, lipid processing, activity sodium proton pump SLC9A1/NHE1, are indispensable for structural functional cohesion as they contribute immensely origin, generation, maintenance, overall acidification surface pH (pHss). As many endogenous exogenous factors can affect pHss, pHss inevitably deviate from optimum. elevation is often accompanied by abnormalities metabolism organization, cohesion, commonly observed eczema, which associated with symptoms dry skin, inflammation, pruritus, infection. In psoriasis, it seems that altered well; however, this case, likely be lower than physiological pHss. Due negative an both eczema been suggested maintain at levels utilizing pH-balanced topical cleansers moisturizers improve skin’s benefiting moisturization regeneration organization barrier. principal aim review gather understanding existing research stimulate critical thinking inspire innovative ideas about ‘known unknowns’, considering intricate nature, prime human health, well pathogenesis psoriasis.

Язык: Английский

---

Type 2 Inflammation and Its Role in Dermatologic Diseases

International Journal of Dermatology, Год журнала: 2025, Номер unknown

Опубликована: Март 22, 2025

Atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria are immune-mediated, inflammatory skin conditions characterized by intense itch disease-specific lesions. Despite their different clinical presentations, the three diseases unified an aberrant type 2 immune response involving cytokines, cells, sensory nerves that may underlie shared manifestations of inflammation pruritus. The nature these is associated with significant impairment in patients' quality life psychological disorders, such as anxiety depression. This article reviews its role atopic urticaria, focusing on pathophysiologic drivers each dermatologic condition. Understanding mechanisms seemingly distinct other concomitant critical for applying therapeutic interventions targeting pathway.

Язык: Английский

---